Your trusted destination for CME, CPD & Medical Education across the Middle East.
Sheikh Shakhbout Medical City, Abu Dhabi, UAE
Nadeen Mamon Omar, MSc is a UAE-based IBD (Inflammatory Bowel Disease) specialist nurse working within the Department of Gastroenterology at Sheikh Shakhbout Medical City (SSMC), Abu Dhabi, UAE. She is involved in multidisciplinary IBD care and clinical research, with a particular focus on improving treatment outcomes and patient experience for people living with Crohn’s disease and ulcerative colitis. The official SSMC conference program lists her as an IBD Registered Nurse.
Her research affiliations consistently identify her with the Department of Gastroenterology, Sheikh Shakhbout Medical City, Abu Dhabi.
Nadeen's work focuses on specialized care for patients with inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Her role is part of a multidisciplinary IBD service involving gastroenterologists, nurses and other healthcare professionals. Research from her SSMC team describes the development of a structured tertiary IBD service that includes an IBD-trained clinical nurse specialist as part of the dedicated care model.
Her professional interests include:
Nadeen Mamon Omar has developed a notable research portfolio in IBD, particularly concerning real-world treatment outcomes in Middle Eastern and UAE populations. Her publications are affiliated with SSMC's Department of Gastroenterology.
In 2026, she co-authored a prospective study investigating subcutaneous infliximab in a Middle Eastern IBD cohort. The study examined patients switching from intravenous infliximab as well as patients starting subcutaneous treatment and was published in Crohn's & Colitis 360.
She also contributed to a 2026 prospective multicentre study evaluating the real-world effectiveness of guselkumab for induction of remission in Crohn's disease, including a propensity-score comparison with risankizumab.
Nadeen is a co-author of research examining the changing use, persistence and outcomes of advanced therapies for IBD in the UAE between 2015 and 2025. The study provides a decade-long view of treatment patterns in a UAE tertiary IBD population.
In 2025, she co-authored a study titled “Assessing the unique concerns of Arab patients with inflammatory bowel disease: A cross-sectional study and the case for region-specific support groups.” The research examined concerns among Arab patients with IBD and highlighted the importance of culturally and regionally appropriate patient-support approaches.
She was also a co-author of research investigating the real-world effectiveness of risankizumab in Crohn's disease, providing treatment-outcome data from a Middle Eastern cohort.
Her work is particularly relevant to the development of specialized IBD services in the UAE. Research from her SSMC team describes efforts to establish a structured tertiary IBD service, including dedicated IBD-trained clinical nursing support. This model aims to improve coordination of care and outcomes for patients with chronic gastrointestinal disease.
Nadeen Mamon Omar is listed as a speaker at the 4th SSMC Pharmacy Conference. The official SSMC program identifies her as an IBD Registered Nurse, Sheikh Shakhbout Medical City, and lists her presentation as “Interdisciplinary Experience from GI Clinic.”
Her participation highlights the importance of collaboration between nursing, pharmacy and gastroenterology in managing patients requiring long-term and advanced medication therapies.

SSMC Training Academy
SSMC Training Academy